- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Fr | Polyrizon climbs on Clearmind Deal | - | Baystreet.ca | ||
| Fr | Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders | 1 | RTTNews | ||
| Fr | Clearmind und Polyrizon kooperieren bei nasaler MEAI-Formulierung | 1 | Investing.com Deutsch | ||
| Fr | Clearmind partners with Polyrizon to develop intranasal MEAI formulation | 1 | Investing.com | ||
| Fr | Polyrizon to develop intranasal formulation of Clearmind's MEAI drug | 2 | Investing.com | ||
| Fr | Polyrizon entwickelt nasale Formulierung für Clearminds Wirkstoffkandidaten MEAI | 1 | Investing.com Deutsch | ||
| Fr | Polyrizon Ltd.: Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation | 82 | GlobeNewswire (Europe) | Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06... ► Artikel lesen | |
| Mi | Polyrizon intends to acquire 51% stake in global private aviation company | 2 | Seeking Alpha | ||
| Mi | Polyrizon signs MOU to acquire 51% stake in Arrow Aviation | 4 | Investing.com | ||
| Mi | Polyrizon Ltd.: Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company | 2 | GlobeNewswire (USA) | ||
| Mi | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | Polyrizon begins usability study for intranasal allergy blocker | 1 | Investing.com | ||
| 22.01. | Polyrizon Ltd.: Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker | 1 | GlobeNewswire (USA) | ||
| 22.01. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.01. | Polyrizon Ltd.: Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet | 2 | GlobeNewswire (USA) | ||
| 08.01. | Polyrizon Ltd.: Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX | 3 | GlobeNewswire (USA) | ||
| 05.01. | Positive Studiendaten zu Allergie-Blocker beflügeln Polyrizon-Aktie | 2 | Investing.com Deutsch | ||
| 05.01. | Polyrizon's nasal allergy blocker outperforms standard in lab study | 1 | Investing.com | ||
| 05.01. | Polyrizon Ltd.: Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator | 1 | GlobeNewswire (USA) | ||
| 05.01. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,510 | -3,21 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BIOXXMED | 1,328 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) |
PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | -5,49 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 20,600 | -7,21 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,750 | +17,98 % | Oragenics, Inc.: Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program | ||
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| SERES THERAPEUTICS | 11,080 | -4,65 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| EDESA BIOTECH | 0,915 | -3,68 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2025 Results | TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,350 (+2,82 %) liegt der Kurs bei 12,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.